Welcome to our dedicated page for Ikena Oncology news (Ticker: IKNA), a resource for investors and traders seeking the latest updates and insights on Ikena Oncology stock.
This page provides a historical news archive for Ikena Oncology, Inc., which traded on Nasdaq under the symbol IKNA before its merger with Inmagene Biopharmaceuticals and subsequent name change to neBio, Inc. The articles collected here trace how Ikena evolved from a targeted oncology company into part of a broader clinical-stage biotechnology organization whose stock now trades under the ticker IMA.
Earlier news under IKNA focuses on Ikena’s targeted oncology programs, including IK-930, a TEAD1-selective Hippo pathway inhibitor, and IK-595, a MEK-RAF molecular glue studied in patients with RAS and RAF mutant cancers. Releases detail clinical progress such as Phase 1 dose escalation, pharmacokinetics and pharmacodynamics observations, and strategic decisions like the discontinuation of IK-930 and workforce restructuring. Financial updates outline Ikena’s cash position, research and development spending, and its evaluation of strategic options for the company and its pipeline.
Subsequent news documents the agreement and completion of a merger with Inmagene Biopharmaceuticals, the approval of the transaction by Ikena stockholders, and the implementation of a 1-for-12 reverse stock split. Coverage explains that the combined company would operate as neBio, Inc., focus on developing -007, a non-depleting anti-OX40 monoclonal antibody for immunological and inflammatory diseases, and trade on Nasdaq under the symbol IMA. Additional items describe the establishment of contingent value rights for Ikena’s legacy assets and governance and compensation plans for the combined company.
Investors and researchers can use this IKNA news archive to follow the sequence of clinical, financial, and corporate events that led from Ikena’s oncology-focused operations to its transformation into neBio, Inc. and the shift in emphasis toward immunological and inflammatory disease programs centered on -007.
Ikena Oncology, a targeted oncology company, will present at the Piper Sandler 34th Annual Healthcare Conference in New York, NY, from November 29 to December 1, 2022. Management will provide a corporate overview on November 29 at 12:10 p.m. ET. The presentation will focus on their novel therapies aimed at treating cancer, particularly through their lead program, IK-930, a TEAD inhibitor targeting the Hippo signaling pathway. Investors can access the live webcast on Ikena's website, which will be archived for 90 days.
Ikena Oncology presented promising clinical data regarding IK-175 for treating urothelial carcinoma at the SITC Annual Meeting. In a cohort of 43 patients, the combination with nivolumab resulted in a 20% overall response rate (ORR) and 40% disease control rate (DCR). Notably, IK-175 monotherapy showed a confirmed partial response lasting 14.9 months. The drug was well tolerated, with manageable side effects. This collaboration may significantly enhance treatment options for patients who have exhausted existing therapies, with Bristol Myers Squibb eligible for opt-in by early 2024.
On November 7, 2022, Ikena Oncology (Nasdaq: IKNA) reported its third-quarter financial results, highlighting progress in clinical trials for its AHR antagonist IK-175 and the targeted therapy IK-930. Initial data indicate that IK-175 shows anti-tumor activity and is well-tolerated in heavily pre-treated patients with urothelial carcinoma. The company has $174.4 million in cash, expected to last through mid-2024, despite an operating cash burn of $17.2 million in Q3 2022. Increased research and development expenses reflect expanded activities in their clinical pipeline.
Ikena Oncology (Nasdaq: IKNA) reported third-quarter financial results for 2022, highlighting ongoing clinical developments for its AHR antagonist, IK-175, which shows promising anti-tumor activity and is well-tolerated in patients with urothelial carcinoma. The company has $174.4 million in cash, sufficient to fund operations through mid-2024. R&D expenses rose to $18.9 million, reflecting increased headcount and manufacturing activity. Ikena anticipates announcing a new development candidate in the RAS pathway by the end of 2022.
Ikena Oncology (Nasdaq: IKNA) presented preclinical data on its novel TEAD inhibitor, IK-930, at the EORTC-NCI-AACR Symposium in Barcelona. The presentation highlighted IK-930’s ability to enhance anti-tumor activity in combination with EGFR and MEK inhibitors, particularly in KRAS and EGFR mutant tumor models. Key findings showed that IK-930 can block compensatory responses to targeted therapies and reduce resistant cancer cell populations. Currently undergoing a Phase 1 clinical trial, IK-930 aims to combat therapeutic resistance in patients with advanced solid tumors.
Ikena Oncology announced a clinical collaboration with AstraZeneca to evaluate IK-930 in combination with osimertinib for EGFR-mutant lung cancer patients. IK-930 is a selective TEAD inhibitor designed to enhance treatment outcomes for patients who are resistant to existing therapies. The ongoing Phase 1 trial aims to explore IK-930’s potential effectiveness as a monotherapy and in combination with targeted therapies to address therapeutic resistance, particularly in non-small cell lung cancer. Initial clinical data is expected in 2023.
Ikena Oncology, Inc. (Nasdaq: IKNA) announced the presentation of two abstracts at the SITC 37th Annual Meeting from November 8-12, 2022. The abstracts will highlight initial results from the Phase 1a/b study of IK-175, an oral AHR antagonist, and its combination with nivolumab for patients with advanced solid tumors, including urothelial carcinoma. Additionally, a trial-in-progress poster will cover an ongoing head and neck cancer study involving IK-175. This program aims to enhance patient-directed cancer treatment by modulating tumor microenvironments.
BOSTON, Sept. 06, 2022 – Ikena Oncology (Nasdaq: IKNA) announced participation in two investor conferences in New York, NY. Management will attend the H.C. Wainwright 24th Annual Global Investment Conference and the Morgan Stanley 20th Annual Global Healthcare Conference. Both events occur from September 12-14, 2022, with a fireside chat hosted by CEO Mark Manfredi on September 14 at 11:45 a.m. ET. The presentation will be available for replay via Ikena's website for 90 days following the live event.
Ikena Oncology (Nasdaq: IKNA) reported its Q2 2022 financial results, showing a cash position of $192.8 million, down from $232.2 million at year-end 2021. The company is advancing its clinical pipeline, particularly IK-930, a TEAD inhibitor, which received Fast Track designation for NF2-deficient mesothelioma. The Phase 1 trials for IK-175, an AHR antagonist partnered with Bristol Myers Squibb, continue with plans to present initial data soon. Operating expenses rose to $19.5 million, up from $15.7 million year-over-year, primarily due to increased personnel and operational costs.
BOSTON, July 6, 2022 – Ikena Oncology, a targeted oncology firm, announced that CEO Mark Manfredi will join a panel at the William Blair Biotech Focus Conference on July 13, 2022. The panel, titled Next Generation Small Molecules in Oncology, is scheduled from 12:00 p.m. to 12:30 p.m. ET. In addition, management will hold one-on-one investor meetings during the conference. Ikena focuses on innovative therapies targeting cancer pathways, with its leading program, IK-930, addressing the Hippo signaling pathway, and additional projects in collaboration with major partners.